Innate Pharma SA (IPHA) stock

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.59+0.05 (+3.25%)

Close on Nov 11, 2026Market cap $149.01MP/E –Yield –

Innate Pharma EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Innate Pharma's EV/EBITDA was 2.4× on Feb 28, 2022, against 6.5× a year earlier. Over the last 2 years it ranged from 0.9× to 17.5×, with a median of 5.1×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2022	Feb 28, 2022	2.4×	−1.3
2021	Dec 31, 2021	3.7×	+2.5
2020	Dec 31, 2020	1.2×	−13.6
2019	Dec 31, 2019	14.7×	–

Where these numbers come from

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Compare: IPHA vs MOLN · IPHA vs TCRX · IPHA vs EVAX · IPHA vs CRBU · IPHA vs CRIS

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Company	Revenue	Growth
CRBU	$9.44M	+1.6%
IPHA	€9.01M	-55.2%
TCRX	$5.19M	-38.4%
CRIS	$4.31M	-62.2%
MOLN	–	–
EVAX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 181
Auditor: Deloitte & Associes
SEC CIK: 1598599

Advertisement
300 × 250

See a number that looks wrong?

Innate Pharma EV/EBITDA

EV/EBITDA at the end of each year

More Innate Pharma figures